Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA
- PMID: 2157956
- DOI: 10.1007/BF00280363
Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA
Abstract
Bacteriophage T4 provides a simple model system in which to examine the mechanism of action of antitumor agents that have been proposed to attack type II DNA topoisomerases. Prior results demonstrated that T4 type II DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in phage-infected Escherichia coli: a point mutation in topoisomerase structural gene 39 was shown to confer both m-AMSA-resistant phage growth and m-AMSA-insensitive topoisomerase activity. We report here that a point mutation in T4 topoisomerase structural gene 52 can also independently render both phage growth and topoisomerase activity resistant to m-AMSA. The DNA relaxation and DNA cleavage activities of this newly isolated mutant topoisomerase were significantly insensitive to m-AMSA. The drug-resistance mutation in gene 52, as well as that in gene 39, alters the DNA cleavage site specificity of wild-type T4 topoisomerase. This finding is consistent with a mechanism of drug action in which both topoisomerase and DNA participate in formation of the drug-binding site.
Similar articles
-
Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli.Proc Natl Acad Sci U S A. 1989 Feb;86(4):1307-11. doi: 10.1073/pnas.86.4.1307. Proc Natl Acad Sci U S A. 1989. PMID: 2537494 Free PMC article.
-
Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases.J Biol Chem. 1990 Nov 25;265(33):20496-505. J Biol Chem. 1990. PMID: 2173709
-
Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.Cancer Res. 1998 Mar 15;58(6):1260-7. Cancer Res. 1998. PMID: 9515814
-
Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.Biochim Biophys Acta. 1998 Oct 1;1400(1-3):339-47. doi: 10.1016/s0167-4781(98)00145-6. Biochim Biophys Acta. 1998. PMID: 9748648 Review.
-
Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1041-7. doi: 10.1016/0360-3016(86)90222-1. Int J Radiat Oncol Biol Phys. 1986. PMID: 2427489 Review.
Cited by
-
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.Cancer Chemother Pharmacol. 1993;32(2):103-8. doi: 10.1007/BF00685611. Cancer Chemother Pharmacol. 1993. PMID: 8387398 Review. No abstract available.
-
A species barrier between bacteriophages T2 and T4: exclusion, join-copy and join-cut-copy recombination and mutagenesis in the dCTPase genes.Genetics. 1998 Apr;148(4):1461-73. doi: 10.1093/genetics/148.4.1461. Genetics. 1998. PMID: 9560366 Free PMC article.
-
Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.Br J Cancer. 1993 Mar;67(3):456-63. doi: 10.1038/bjc.1993.87. Br J Cancer. 1993. PMID: 8382508 Free PMC article.
-
Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.EMBO J. 1993 May;12(5):2085-97. doi: 10.1002/j.1460-2075.1993.tb05857.x. EMBO J. 1993. PMID: 8387918 Free PMC article.
-
Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes.Genetics. 1996 Jul;143(3):1081-90. doi: 10.1093/genetics/143.3.1081. Genetics. 1996. PMID: 8807283 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources